A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases.

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Exchange Traded Concepts LLC lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.5% during the 4th ...

Fifth Third Bancorp reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.4% in the fourth quarter, HoldingsChannel reports. The fund owned 3,246 shares of the biotechnology company’s ...

Biogen's efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China's InnoCare last year for $125 ...

Launched in 2018, the Morningstar Minority Empowerment Index highlights companies that demonstrate a strong commitment to ...

Added to its challenges, Biogen is also seeing greater competitive pressures on its multiple sclerosis therapies Tecfidera (dimethyl fumarate) and Tysabri (natalizumab), as well as blockbuster ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 36 tables and 83 figures, this 153-page report ?North America Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...